{"id":20779,"date":"2023-02-22T07:00:00","date_gmt":"2023-02-22T07:00:00","guid":{"rendered":"https:\/\/www.ipsen.com\/press-releases\/ipsen-annonce-lextension-de-son-offre-publique-dachat-pour-les-actions-dalbireo-pharma-inc-au-1er-mars-2023\/"},"modified":"2025-01-30T17:16:07","modified_gmt":"2025-01-30T15:16:07","slug":"ipsen-extends-expiration-date-of-tender-offer-for-albireo-pharma-inc-to-1-march-2023","status":"publish","type":"press_release","link":"https:\/\/www.ipsen.com\/fr\/communique-de-presse\/ipsen-extends-expiration-date-of-tender-offer-for-albireo-pharma-inc-to-1-march-2023\/","title":{"rendered":"Ipsen annonce l\u2019extension de son offre publique d\u2019achat pour les actions d\u2019Albireo Pharma, Inc. au 1er mars 2023"},"content":{"rendered":"\n<p>&nbsp;<strong>Ipsen annonce l\u2019extension de son offre publique d\u2019achat pour les actions d\u2019<\/strong><strong>Albireo<\/strong><strong>&nbsp;Pharma,&nbsp;Inc.&nbsp;<\/strong><strong>au 1er&nbsp;mars&nbsp;2023<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Ce d\u00e9lai suppl\u00e9mentaire permettra de satisfaire la condition&nbsp;HSR, comme le pr\u00e9voit l\u2019accord de fusion.<\/strong><\/li>\n\n\n\n<li><strong>Les actionnaires d\u2019Albireo sont invit\u00e9s \u00e0 apporter leurs actions \u00e0 l\u2019offre d\u00e8s aujourd\u2019hui.<\/strong><\/li>\n<\/ul>\n\n\n\n<p><strong>PARIS, FRANCE, le 22&nbsp;f\u00e9vrier&nbsp;2023&nbsp;<\/strong>\u2013 Ipsen&nbsp;S.A. (Euronext&nbsp;: IPN&nbsp;; ADR&nbsp;: IPSEY) a annonc\u00e9 aujourd\u2019hui que sa filiale d\u00e9tenue indirectement \u00e0 100&nbsp;%, Anemone&nbsp;Acquisition&nbsp;Corp. (\u00ab&nbsp;Acqu\u00e9reur&nbsp;\u00bb), a prolong\u00e9 le d\u00e9lai de validit\u00e9 de son offre publique d\u2019achat annonc\u00e9e pr\u00e9c\u00e9demment en vue d\u2019acqu\u00e9rir la totalit\u00e9 des actions ordinaires \u00e9mises et en circulation (\u00ab&nbsp;Actions&nbsp;\u00bb) d\u2019Albireo&nbsp;Pharma,&nbsp;Inc. (NASDAQ&nbsp;: ALBO) (\u00ab&nbsp;Albireo&nbsp;\u00bb) au prix net de 42,00&nbsp;$ par action, payable au d\u00e9tenteur en num\u00e9raire, sans int\u00e9r\u00eat et apr\u00e8s les retenues \u00e0 la source applicables, auquel s\u2019ajoute un Certificat de Valeur Garantie (CVG) par Action contractuel non transf\u00e9rable, jusqu\u2019\u00e0 23h59, heure de l\u2019Est, le mercredi&nbsp;1<sup>er<\/sup>&nbsp;mars&nbsp;2023, sauf en cas de nouvelle prolongation. L\u2019offre publique d\u2019achat devait auparavant expirer une minute apr\u00e8s 23h59, heure de l\u2019Est, le mardi 21&nbsp;f\u00e9vrier&nbsp;2023. L\u2019ensemble des autres modalit\u00e9s et conditions de l\u2019offre publique d\u2019achat restent inchang\u00e9es.<\/p>\n\n\n\n<p>Chaque CVG donnera droit \u00e0 son d\u00e9tenteur \u00e0 un paiement unique en num\u00e9raire, de 10,00&nbsp;$ net par CVG, sans int\u00e9r\u00eat et apr\u00e8s les retenues \u00e0 la source applicables, sous r\u00e9serve de l\u2019atteinte d\u2019une certaine \u00e9tape dont les conditions sont d\u00e9crites dans l\u2019offre publique d\u2019achat dat\u00e9e du 23&nbsp;janvier&nbsp;2023 (ainsi que tout compl\u00e9ment ou toute modification \u00e0 l\u2019offre publique d\u2019achat) et dans la lettre d\u2019envoi correspondante.<\/p>\n\n\n\n<p>L\u2019offre publique d\u2019achat a \u00e9t\u00e9 prolong\u00e9e en vue d\u2019accorder un d\u00e9lai suppl\u00e9mentaire afin que la condition relative \u00e0 l\u2019expiration ou \u00e0 la lev\u00e9e de la p\u00e9riode d\u2019attente (et toute prolongation de celle-ci) pr\u00e9vue par la loi&nbsp;am\u00e9ricaine&nbsp;<em>Hart-Scott-Rodino Antitrust Improvements Act<\/em>&nbsp;de 1976 telle qu\u2019amend\u00e9e (\u00ab&nbsp;condition HSR&nbsp;\u00bb) soit satisfaite.<\/p>\n\n\n\n<p>Computershare&nbsp;Trust&nbsp;Company, N.A., d\u00e9positaire et agent payeur de l\u2019offre publique d\u2019achat, a indiqu\u00e9 qu\u2019\u00e0 18h00, heure de l\u2019Est, le 21&nbsp;f\u00e9vrier&nbsp;2023, environ 13.229.445&nbsp;actions avaient \u00e9t\u00e9 valablement apport\u00e9es dans le cadre de l\u2019offre publique d\u2019achat et n\u2019avaient pas \u00e9t\u00e9 valablement retir\u00e9es, soit environ 63&nbsp;% des Actions en circulation au 20&nbsp;janvier&nbsp;2023. Les actionnaires ayant d\u00e9j\u00e0 apport\u00e9 leurs actions dans le cadre de l\u2019offre publique d\u2019achat ne sont pas tenus d\u2019apporter \u00e0 nouveau leurs actions ni de prendre toute autre mesure \u00e0 la suite de la prolongation du d\u00e9lai de validit\u00e9 de l\u2019offre publique d\u2019achat.<\/p>\n\n\n\n<p>L\u2019ex\u00e9cution de l\u2019offre publique d\u2019achat reste soumise \u00e0 d\u2019autres conditions d\u00e9crites dans la d\u00e9claration d\u2019offre publique d\u2019achat en vertu de l\u2019annexe&nbsp;TO, telle qu\u2019elle peut \u00eatre modifi\u00e9e ou compl\u00e9t\u00e9e, qui a \u00e9t\u00e9 d\u00e9pos\u00e9e par l\u2019Acqu\u00e9reur, Ipsen&nbsp;Biopharmaceuticals,&nbsp;Inc., Ipsen&nbsp;Pharma&nbsp;SAS et Ipsen&nbsp;S.A. aupr\u00e8s de la&nbsp;<em>Securities and Exchange Commission<\/em>&nbsp;(SEC) des \u00c9tats-Unis le 23&nbsp;janvier&nbsp;2023.<\/p>\n\n\n\n<p>Les demandes de documents et questions concernant l\u2019offre publique d\u2019achat peuvent \u00eatre adress\u00e9es \u00e0 Georgeson&nbsp;LLC, l\u2019agent d\u2019information d\u00e9sign\u00e9 dans le cadre de l\u2019offre publique d\u2019achat, par t\u00e9l\u00e9phone (gratuit) au (866) 203-9357 ou par e-mail \u00e0 l\u2019adresse&nbsp;<a href=\"mailto:albireopharma@georgeson.com\">albireopharma@georgeson.com<\/a>.<\/p>\n\n\n\n<p><strong>FIN<\/strong><\/p>\n\n\n\n<p><strong>\u00c0 propos d\u2019Ipsen<\/strong><\/p>\n\n\n\n<p>Ipsen est une soci\u00e9t\u00e9 biopharmaceutique mondiale de taille moyenne focalis\u00e9e sur la mise au point de m\u00e9dicaments innovants en Oncologie, dans les Maladies Rares et en Neurosciences. Avec un chiffre d\u2019affaires Groupe de 3,0 milliards d\u2019euros pour l\u2019exercice 2022, Ipsen vend des m\u00e9dicaments dans plus de 100 pays. Outre sa strat\u00e9gie d\u2019innovation externe, les efforts d\u2019Ipsen en mati\u00e8re de R&amp;D sont focalis\u00e9s sur ses plateformes technologiques diff\u00e9renci\u00e9es et innovantes situ\u00e9es au c\u0153ur de clusters mondiaux de la recherche biotechnologique ou en sciences de la vie : Paris-Saclay, France ; Oxford, Royaume-Uni ; Cambridge, \u00c9tats- Unis ; Shanghai, Chine. Ipsen emploie environ 5 000 collaborateurs dans le monde. Ipsen est cot\u00e9 \u00e0 Paris (Euronext : IPN) et aux \u00c9tats-Unis \u00e0 travers un programme d\u2019American Depositary Receipt (ADR : IPSEY) sponsoris\u00e9 de niveau I. Le site Internet d\u2019Ipsen est ipsen.com.<\/p>\n\n\n\n<p><strong>Renseignements compl\u00e9mentaires et sources d\u2019information<\/strong><\/p>\n\n\n\n<p>Le pr\u00e9sent communiqu\u00e9 ne constitue ni une offre d\u2019achat, ni une sollicitation d\u2019offre de vente d\u2019actions, et est publi\u00e9 \u00e0 titre informatif uniquement. L\u2019offre publique d\u2019achat ne sera pas faite, et les apports en r\u00e9ponse \u00e0 l\u2019offre ne seront pas accept\u00e9s, en faveur ou pour le compte de porteurs d\u2019actions dans des juridictions dans lesquelles l\u2019ex\u00e9cution de l\u2019offre publique d\u2019achat ou l\u2019acceptation de celle-ci ne serait pas conforme aux lois de ces juridictions.<\/p>\n\n\n\n<p>L\u2019offre publique d\u2019achat est faite conform\u00e9ment \u00e0 une d\u00e9claration d\u2019offre publique d\u2019achat en vertu de l\u2019annexe&nbsp;TO (y compris une offre d\u2019achat, une lettre d\u2019envoi connexe et d\u2019autres documents relatifs \u00e0 l\u2019offre publique d\u2019achat) d\u00e9pos\u00e9e par l\u2019Acqu\u00e9reur, Ipsen&nbsp;Biopharmaceuticals,&nbsp;Inc., Ipsen&nbsp;Pharma&nbsp;SAS et Ipsen&nbsp;S.A. aupr\u00e8s de la SEC le 23&nbsp;janvier&nbsp;2023, dans sa version modifi\u00e9e ou compl\u00e9t\u00e9e de temps \u00e0 autre. En outre, le 23&nbsp;janvier&nbsp;2023, Albireo a d\u00e9pos\u00e9 aupr\u00e8s de la SEC une d\u00e9claration de sollicitation\/recommendation en vertu de l\u2019annexe&nbsp;14D-9 (pouvant \u00eatre modifi\u00e9e ou compl\u00e9t\u00e9e de temps \u00e0 autre, la \u00ab&nbsp;D\u00e9claration de sollicitation\/recommendation&nbsp;\u00bb) concernant l\u2019offre publique d\u2019achat. LES DOCUMENTS RELATIFS \u00c0 L\u2019OFFRE PUBLIQUE D\u2019ACHAT (COMPRENANT L\u2019OFFRE D\u2019ACHAT, LA LETTRE D\u2019ENVOI CORRESPONDANTE ET D\u2019AUTRES DOCUMENTS RELATIFS \u00c0 L\u2019OFFRE) ET LA D\u00c9CLARATION DE SOLLICITATION\/RECOMMANDATION EN VERTU DE L\u2019ANNEXE 14D-9 CONTIENNENT DES INFORMATIONS IMPORTANTES. IL EST DONC CONSEILL\u00c9 AUX ACTIONNAIRES D\u2019ALBIREO DE LIRE ATTENTIVEMENT CES DOCUMENTS (DANS LEUR VERSION MODIFI\u00c9E OU COMPL\u00c9T\u00c9E DE TEMPS \u00c0 AUTRE) AFIN QUE LES D\u00c9TENTEURS DE TITRES D\u2019ALBIREO TIENNENT COMPTE DE CES INFORMATIONS IMPORTANTES AVANT DE PRENDRE TOUTE D\u00c9CISION CONCERNANT L\u2019APPORT DE LEURS TITRES. L\u2019ensemble des documents relatifs \u00e0 l\u2019offre publique d\u2019achat sont disponibles gratuitement sur le site Web de la SEC \u00e0 l\u2019adresse www.sec.gov.<\/p>\n\n\n\n<p><strong><u>Pour plus d\u2019informations&nbsp;:<\/u><\/strong><\/p>\n\n\n\n<p><strong>Contacts<\/strong><\/p>\n\n\n\n<p><strong><u>Investisseurs<\/u><\/strong><\/p>\n\n\n\n<figure class=\"wp-block-table\"><table><tbody><tr><td><strong>Craig Marks<\/strong>Vice President, Investor Relations+44 (0)7584 349 193<\/td><td><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong><u>M\u00e9dias<\/u><\/strong><\/p>\n\n\n\n<figure class=\"wp-block-table\"><table><tbody><tr><td><strong>Anna&nbsp;Gibbins<\/strong>Global Head of Franchise Communications, Rare Disease+44 7717801900&nbsp;<\/td><td><strong>Ioana&nbsp;Piscociu<\/strong>Senior Manager Global Media&nbsp;Relations+33 6 69 09 12 96&nbsp;<\/td><\/tr><tr><td><strong>Amy&nbsp;Wolf<\/strong>VP, Head of Corporate Brand Strategy+41 79 576 07 23<\/td><\/tr><\/tbody><\/table><\/figure>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":5,"template":"","categories":[1233,3556],"tags":[],"class_list":["post-20779","press_release","type-press_release","status-publish","has-post-thumbnail","hentry","category-pressrelease-fr","category-corporate-pressrelease-fr","entry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Ipsen annonce l\u2019extension de son offre publique d\u2019achat pour les actions d\u2019Albireo Pharma, Inc. au 1er mars 2023<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.ipsen.com\/fr\/communique-de-presse\/ipsen-extends-expiration-date-of-tender-offer-for-albireo-pharma-inc-to-1-march-2023\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Ipsen annonce l\u2019extension de son offre publique d\u2019achat pour les actions d\u2019Albireo Pharma, Inc. au 1er mars 2023\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.ipsen.com\/fr\/communique-de-presse\/ipsen-extends-expiration-date-of-tender-offer-for-albireo-pharma-inc-to-1-march-2023\/\" \/>\n<meta property=\"og:site_name\" content=\"Global\" \/>\n<meta property=\"article:modified_time\" content=\"2025-01-30T15:16:07+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.ipsen.com\/wp-content\/uploads\/2022\/08\/PR-final-fr-1.jpeg\" \/>\n\t<meta property=\"og:image:width\" content=\"1082\" \/>\n\t<meta property=\"og:image:height\" content=\"620\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:site\" content=\"@ipsengroup\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"NewsArticle\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/communique-de-presse\/ipsen-extends-expiration-date-of-tender-offer-for-albireo-pharma-inc-to-1-march-2023\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/communique-de-presse\/ipsen-extends-expiration-date-of-tender-offer-for-albireo-pharma-inc-to-1-march-2023\/\"},\"author\":{\"name\":\"\",\"@id\":\"\"},\"headline\":\"Ipsen annonce l\u2019extension de son offre publique d\u2019achat pour les actions d\u2019Albireo Pharma, Inc. au 1er mars 2023\",\"datePublished\":\"2023-02-22T07:00:00+00:00\",\"dateModified\":\"2025-01-30T15:16:07+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/communique-de-presse\/ipsen-extends-expiration-date-of-tender-offer-for-albireo-pharma-inc-to-1-march-2023\/\"},\"wordCount\":1205,\"publisher\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/#organization\"},\"image\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/communique-de-presse\/ipsen-extends-expiration-date-of-tender-offer-for-albireo-pharma-inc-to-1-march-2023\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.ipsen.com\/wp-content\/uploads\/2022\/08\/PR-final-fr-1.jpeg\",\"articleSection\":[\"Communiqu\u00e9 de presse\",\"Corporate\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/communique-de-presse\/ipsen-extends-expiration-date-of-tender-offer-for-albireo-pharma-inc-to-1-march-2023\/\",\"url\":\"https:\/\/www.ipsen.com\/fr\/communique-de-presse\/ipsen-extends-expiration-date-of-tender-offer-for-albireo-pharma-inc-to-1-march-2023\/\",\"name\":\"Ipsen annonce l\u2019extension de son offre publique d\u2019achat pour les actions d\u2019Albireo Pharma, Inc. au 1er mars 2023\",\"isPartOf\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/communique-de-presse\/ipsen-extends-expiration-date-of-tender-offer-for-albireo-pharma-inc-to-1-march-2023\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/communique-de-presse\/ipsen-extends-expiration-date-of-tender-offer-for-albireo-pharma-inc-to-1-march-2023\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.ipsen.com\/wp-content\/uploads\/2022\/08\/PR-final-fr-1.jpeg\",\"datePublished\":\"2023-02-22T07:00:00+00:00\",\"dateModified\":\"2025-01-30T15:16:07+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/communique-de-presse\/ipsen-extends-expiration-date-of-tender-offer-for-albireo-pharma-inc-to-1-march-2023\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.ipsen.com\/fr\/communique-de-presse\/ipsen-extends-expiration-date-of-tender-offer-for-albireo-pharma-inc-to-1-march-2023\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/communique-de-presse\/ipsen-extends-expiration-date-of-tender-offer-for-albireo-pharma-inc-to-1-march-2023\/#primaryimage\",\"url\":\"https:\/\/www.ipsen.com\/wp-content\/uploads\/2022\/08\/PR-final-fr-1.jpeg\",\"contentUrl\":\"https:\/\/www.ipsen.com\/wp-content\/uploads\/2022\/08\/PR-final-fr-1.jpeg\",\"width\":1082,\"height\":620},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/communique-de-presse\/ipsen-extends-expiration-date-of-tender-offer-for-albireo-pharma-inc-to-1-march-2023\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.ipsen.com\/fr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Ipsen annonce l\u2019extension de son offre publique d\u2019achat pour les actions d\u2019Albireo Pharma, Inc. au 1er mars 2023\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/#website\",\"url\":\"https:\/\/www.ipsen.com\/fr\/\",\"name\":\"Global\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.ipsen.com\/fr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/#organization\",\"name\":\"IPSEN\",\"url\":\"https:\/\/www.ipsen.com\/fr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.ipsen.com\/wp-content\/uploads\/2023\/12\/Latest_Ipsen-logo_168x48.svg\",\"contentUrl\":\"https:\/\/www.ipsen.com\/wp-content\/uploads\/2023\/12\/Latest_Ipsen-logo_168x48.svg\",\"caption\":\"IPSEN\"},\"image\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/Ipsengroup\",\"https:\/\/x.com\/ipsengroup\"]},{\"@type\":\"Person\",\"@id\":\"\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Ipsen annonce l\u2019extension de son offre publique d\u2019achat pour les actions d\u2019Albireo Pharma, Inc. au 1er mars 2023","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.ipsen.com\/fr\/communique-de-presse\/ipsen-extends-expiration-date-of-tender-offer-for-albireo-pharma-inc-to-1-march-2023\/","og_locale":"fr_FR","og_type":"article","og_title":"Ipsen annonce l\u2019extension de son offre publique d\u2019achat pour les actions d\u2019Albireo Pharma, Inc. au 1er mars 2023","og_url":"https:\/\/www.ipsen.com\/fr\/communique-de-presse\/ipsen-extends-expiration-date-of-tender-offer-for-albireo-pharma-inc-to-1-march-2023\/","og_site_name":"Global","article_modified_time":"2025-01-30T15:16:07+00:00","og_image":[{"width":1082,"height":620,"url":"https:\/\/www.ipsen.com\/wp-content\/uploads\/2022\/08\/PR-final-fr-1.jpeg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_site":"@ipsengroup","twitter_misc":{"Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"NewsArticle","@id":"https:\/\/www.ipsen.com\/fr\/communique-de-presse\/ipsen-extends-expiration-date-of-tender-offer-for-albireo-pharma-inc-to-1-march-2023\/#article","isPartOf":{"@id":"https:\/\/www.ipsen.com\/fr\/communique-de-presse\/ipsen-extends-expiration-date-of-tender-offer-for-albireo-pharma-inc-to-1-march-2023\/"},"author":{"name":"","@id":""},"headline":"Ipsen annonce l\u2019extension de son offre publique d\u2019achat pour les actions d\u2019Albireo Pharma, Inc. au 1er mars 2023","datePublished":"2023-02-22T07:00:00+00:00","dateModified":"2025-01-30T15:16:07+00:00","mainEntityOfPage":{"@id":"https:\/\/www.ipsen.com\/fr\/communique-de-presse\/ipsen-extends-expiration-date-of-tender-offer-for-albireo-pharma-inc-to-1-march-2023\/"},"wordCount":1205,"publisher":{"@id":"https:\/\/www.ipsen.com\/fr\/#organization"},"image":{"@id":"https:\/\/www.ipsen.com\/fr\/communique-de-presse\/ipsen-extends-expiration-date-of-tender-offer-for-albireo-pharma-inc-to-1-march-2023\/#primaryimage"},"thumbnailUrl":"https:\/\/www.ipsen.com\/wp-content\/uploads\/2022\/08\/PR-final-fr-1.jpeg","articleSection":["Communiqu\u00e9 de presse","Corporate"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/www.ipsen.com\/fr\/communique-de-presse\/ipsen-extends-expiration-date-of-tender-offer-for-albireo-pharma-inc-to-1-march-2023\/","url":"https:\/\/www.ipsen.com\/fr\/communique-de-presse\/ipsen-extends-expiration-date-of-tender-offer-for-albireo-pharma-inc-to-1-march-2023\/","name":"Ipsen annonce l\u2019extension de son offre publique d\u2019achat pour les actions d\u2019Albireo Pharma, Inc. au 1er mars 2023","isPartOf":{"@id":"https:\/\/www.ipsen.com\/fr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.ipsen.com\/fr\/communique-de-presse\/ipsen-extends-expiration-date-of-tender-offer-for-albireo-pharma-inc-to-1-march-2023\/#primaryimage"},"image":{"@id":"https:\/\/www.ipsen.com\/fr\/communique-de-presse\/ipsen-extends-expiration-date-of-tender-offer-for-albireo-pharma-inc-to-1-march-2023\/#primaryimage"},"thumbnailUrl":"https:\/\/www.ipsen.com\/wp-content\/uploads\/2022\/08\/PR-final-fr-1.jpeg","datePublished":"2023-02-22T07:00:00+00:00","dateModified":"2025-01-30T15:16:07+00:00","breadcrumb":{"@id":"https:\/\/www.ipsen.com\/fr\/communique-de-presse\/ipsen-extends-expiration-date-of-tender-offer-for-albireo-pharma-inc-to-1-march-2023\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.ipsen.com\/fr\/communique-de-presse\/ipsen-extends-expiration-date-of-tender-offer-for-albireo-pharma-inc-to-1-march-2023\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.ipsen.com\/fr\/communique-de-presse\/ipsen-extends-expiration-date-of-tender-offer-for-albireo-pharma-inc-to-1-march-2023\/#primaryimage","url":"https:\/\/www.ipsen.com\/wp-content\/uploads\/2022\/08\/PR-final-fr-1.jpeg","contentUrl":"https:\/\/www.ipsen.com\/wp-content\/uploads\/2022\/08\/PR-final-fr-1.jpeg","width":1082,"height":620},{"@type":"BreadcrumbList","@id":"https:\/\/www.ipsen.com\/fr\/communique-de-presse\/ipsen-extends-expiration-date-of-tender-offer-for-albireo-pharma-inc-to-1-march-2023\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.ipsen.com\/fr\/"},{"@type":"ListItem","position":2,"name":"Ipsen annonce l\u2019extension de son offre publique d\u2019achat pour les actions d\u2019Albireo Pharma, Inc. au 1er mars 2023"}]},{"@type":"WebSite","@id":"https:\/\/www.ipsen.com\/fr\/#website","url":"https:\/\/www.ipsen.com\/fr\/","name":"Global","description":"","publisher":{"@id":"https:\/\/www.ipsen.com\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.ipsen.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.ipsen.com\/fr\/#organization","name":"IPSEN","url":"https:\/\/www.ipsen.com\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.ipsen.com\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/www.ipsen.com\/wp-content\/uploads\/2023\/12\/Latest_Ipsen-logo_168x48.svg","contentUrl":"https:\/\/www.ipsen.com\/wp-content\/uploads\/2023\/12\/Latest_Ipsen-logo_168x48.svg","caption":"IPSEN"},"image":{"@id":"https:\/\/www.ipsen.com\/fr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/Ipsengroup","https:\/\/x.com\/ipsengroup"]},{"@type":"Person","@id":""}]}},"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/press_release\/20779","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/press_release"}],"about":[{"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/types\/press_release"}],"author":[{"embeddable":true,"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/users\/5"}],"version-history":[{"count":1,"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/press_release\/20779\/revisions"}],"predecessor-version":[{"id":62855,"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/press_release\/20779\/revisions\/62855"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/media\/27874"}],"wp:attachment":[{"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/media?parent=20779"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/categories?post=20779"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/tags?post=20779"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}